CoronaVac
- Generic Name
- CoronaVac
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- M1QXB372B8
- Background
CoronaVac, previously known as PiCoVacc, is a SARS-CoV-2 purified, inactivated, and adsorbed vaccine candidate developed by SinoVac Biotech Corporation. It was developed by propagating the SARS-CoV-2 CN2 strain inside Vero Cells and inactivating it with B-propiolactone. In preclinical trials, PiCoVacc induced SARS-CoV-2-specific neutralizing antibodies in rats, mice, and the rhesus macaque. The antibodies were found to neutralize 10 representative SARS-CoV-2 strains. As of August 2020, the vaccine is being tested in numerous human clinical trials assessing its safety and immunogenicity.
- Associated Conditions
- -
- Associated Therapies
- -
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and ...
Sinovac Biotech Ltd. initiated a Phase III clinical trial for a multivalent HFMD vaccine targeting EV71 and CA16, the first of its kind globally. The trial aims to assess efficacy, safety, and immunogenicity in children aged 6-71 months. Previous Phase I/II trials showed favorable safety and immunogenicity. Sinovac is also developing a tetravalent enterovirus vaccine to cover additional HFMD-causing viruses.
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and
Sinovac Biotech initiates Phase III trial for world's first multivalent HFMD vaccine targeting EV71 and CA16, following favorable Phase I/II results. The company also develops a tetravalent vaccine for EV71, CA16, CA10, and CA6, aiming to enhance protection for children.
FAQs on COVID-19 Vaccination: Types, Eligibility, and Importance
COVID-19 vaccination is crucial for public health, reducing hospitalization and death. Vaccines include mRNA, inactivated, viral vector, and protein subunit types. Eligibility starts at 6 months, with specific doses for different age groups. The government provides mRNA vaccines for additional boosters, emphasizing timely vaccination for protection against variants like JN.1.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath